SS Innovations International, Inc. (SSII) announced that its SSi Mantra surgical robotic system has received regulatory approval to perform telesurgeries in Indonesia and the Philippines. The approvals were granted on June 13 2024 for Indonesia and March 28 2025 for the Philippines, and the company’s announcement on March 18 2026 clarified that both markets are now cleared for remote robotic surgery.
The company has performed more than 150 cumulative telesurgeries with the SSi Mantra system. Earlier milestones include the first inter‑continental cardiac telesurgery, India’s first north‑to‑south robotic cardiac telesurgery covering 2,000 kilometers on April 3 2025, and high‑volume events such as 18 inter‑hospital telesurgeries between two Indian cities on February 14 2026 and a marathon of 24 telesurgeries by nine surgeons on December 23 2025.
Financially, SSII reported fiscal‑year 2025 revenue of $42.5 million, a 105.7% increase from fiscal‑year 2024, and a net loss of $12.1 million, an improvement from the $19.2 million loss in fiscal‑year 2024. The company recently raised approximately $18.6 million through a private placement to fund growth initiatives, leaving $3.2 million in cash and equivalents at year‑end.
SSII is actively pursuing FDA 510(k) clearance in the United States, with a review expected in mid‑2026, and CE Mark certification in the European Union, anticipated in late 2025 or mid‑2026. Successful entry into these markets would open significant new revenue opportunities.
"The SSi Mantra surgical robotic system continues to pioneer telesurgery, not merely in concept but in real‑world practice and rapidly growing adoption by leading physicians. We are thrilled to receive approval for telesurgeries utilizing the SSi Mantra in two new markets: Indonesia and the Philippines," said Dr. Sudhir Srivastava, Chairman and CEO.
"Among our accomplishments in 2025, we gained significant share of the surgical robotics market in India, expanded into new global geographies, and progressed along the regulatory pathways required for entering the United States and European Union markets," added Dr. Srivastava during the earnings call.
"In conclusion, we expect continuing strong growth in 2026 as we deploy the SSi Mantra in existing and new markets, increasing access to world‑class surgical robotic care," he concluded.
Investors reacted negatively to the announcement, reflecting concerns about the company’s ongoing net losses and limited cash reserves despite the regulatory expansion.
The approvals reinforce SSII’s strategy of expanding into emerging markets while it continues to build a robust telesurgery portfolio and pursue entry into the U.S. and EU markets. The company’s ability to secure regulatory clearance in multiple jurisdictions positions it to capture a growing share of the global telesurgery market, though its financial performance remains a key focus for stakeholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.